Login / Signup

Cost-effective Analysis of Subcutaneous vs Sublingual Immunotherapy From the Payor's Perspective.

Frances Mei HardinPeter N EskanderChristine Franzese
Published in: OTO open (2021)
When compared to SCIT, SLIT is economically favorable and should be considered the financially conscious option for patients with >40% adherence to therapy.
Keyphrases
  • stem cells
  • metabolic syndrome
  • mesenchymal stem cells
  • cell therapy
  • insulin resistance
  • replacement therapy
  • smoking cessation